ZyVersa Therapeutics Plunges 10.7% Amid Funding Deal

On June 26, 2025, ZyVersa Therapeutics experienced a significant drop of 10.7% in pre-market trading, reflecting investor sentiment and market dynamics.

ZyVersa Therapeutics has recently entered into a share purchase agreement with Williamsburg Venture Holdings, securing up to $10 million in funding. This partnership aims to advance the clinical development of VAR 200, a treatment for chronic kidney diseases. The agreement allows ZyVersa to sell up to $10 million in common stock over a 24-month period, providing a flexible source of funding while minimizing dilution for shareholders. The company will issue 2.5% of commitment shares to Williamsburg Venture Holdings based on the percentage of the $10 million of common stock purchased.

This strategic move is expected to support ZyVersa's ongoing clinical development efforts, particularly for VAR 200, which is designed to treat chronic kidney diseases. The company anticipates that this funding will enable it to achieve key milestones in its clinical trials, ultimately creating and sustaining shareholder value. The agreement provides ZyVersa with the discretion to control the timing and amount of all sales of common stock, ensuring a judicious approach to equity sales.